Date: 2015-12-16
Type of information: R&D agreement
Compound: undisclosed
Company: Crispr Therapeutics (Switzerland - UK) Genethon (France)
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease: undisclosed
Details: * On December 16th, 2015, Généthon, a leader in the field of gene therapy treatments for rare diseases, and CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for patients with serious diseases, have announced an ongoing research collaboration. Généthon is supporting the development of one CRISPR Therapeutics’ undisclosed propriety programs. Généthon’s expertise is in the pre-clinical development, clinical development and production of gene therapy products.
Financial terms:
Latest news:
